geboren 1964 in Meldorf

Ausbildung und Qualifikationen

Beruflicher Werdegang

Preise

Forschungsschwerpunkt

Colo-rektale Karzinome, Maligne Lymphome, insbesondere die Planung und Durchführung von klinischen Studien in den Phasen I-III zur Primär- und Rezidivtherapie bei Patienten mit Non-Hodgkin-Lymphomen, Hodgkin-Lymphomen und CLL. Antikörper-gestützte Immuntherapie.

Mitgliedschaften

• Deutsche Gesellschaft für Innere Medizin
• Deutsche Gesellschaft für Hämatologie und Onkologie
• Deutsche Gesellschaft für Palliativmedizin
• Deutsche Krebsgesellschaft, Arbeitsgemeinschaft Internistischer Onkologen
• Berufsverband der niedergelassenen Hämatologen und Onkologen
• Berufsverband der niedergelassenen Hämatologen und Onkologen Nordrhein (NIONo)
• European Hematology Association
• European Society of Medical Oncology
• European Association of Palliative Care
• American Society of Hematology

Verzeichnis der wissenschaftlichen Veröffentlichungen

1. In referierten Journalen publizierte Originalarbeiten

• Weide R, Schnell R, Schardt C, Koenigsmann M, Otremba B, Zahn MO, Wierecky J, Braun U, Hensel M, Klausmann M, Fleckenstein D, Ehscheidt P, Feiten S.  Health status and infections in patients with symptomatic primary and secondary immunoglobulin G (IgG) deficiencies receiving intravenous IgG replacement.BMC Immunology 2020, 1, Article number: 39 
• Nogova L, Mattonet C, Scheffler M, Taubert M, Gardizi M, Sos ML, Michels S, Fischer RN, Limburg M, Abdulla DSY, Persigehl T, Kobe C, Merkelbach-Bruse S, Franklin J, Backes H, Schnell R, Behringer D, Kaminsky B, Eichstaedt M, Stelzer C, Kinzig M, Sörgel F, Tian Y, Junge L, Suleiman AA, Frechen S, Rokitta D, Ouyang D, Fuhr U, Buettner R, Wolf J, Sorafenib and everolimus in patients with advanced solid tumor and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG_PET assessment. Cancer Med. 2020 May 21.
• Kurbacher CM, Reichelt R, Schnell R; The need for psycho-oncological support in breast cancer patients – a longitudinal study in an outpatient- setting. J. Psychology and Mental Health Care 2019. Doi: 10.31579/2637-8892/038.
• von Verschuer U, Schnell R, Tessen HW, Eggert J, Binninger A, Spring L, Jänicke M, Marschner N; TLK-Group (Tumour Registry Lung Cancer). Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer - final results from the prospective German TLK cohort study. Lung Cancer. 2017 Aug 22. pii: S0169-5002(17)30419-1
• Scheffler M, Schultheis A, Teixido C, Michels S, Morales-Espinosa D, Viteri S, Hartmann W, Merkelbach-Bruse S, Fischer R, Schildhaus HU, Fassunke J, Sebastian M, Serke M, Kaminsky B, Randerath W, Gerigk U, Ko YD, Krüger S, Schnell R, Rothe A, Kropf-Sanchen C, Heukamp L, Rosell R, Büttner R, Wolf J. ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability. Oncotarget. 2015 Apr 30;6(12):10577-85.
• Böll B, Goergen H, Arndt N, Meissner J, Krause SW, Schnell R, von Tresckow B, Eichenauer DA, Sasse S, Fuchs M, Behringer K, Klimm BC, Naumann R, Diehl V, Engert A, Borchmann P. Relapsed Hodgkin Lymphoma in Older Patients: A Comprehensive Analysis From the German Hodgkin Study Group. J Clin Oncol. 2013; 31(35):4431-7.
• Seidel D, Zander T, Heukamp LC, Peifer M, Bos M, Fernández-Cuesta L, Leenders F, Lu X, Ansén S, Gardizi M, Nguyen C, Berg J, Russell P, Wainer Z, Schildhaus HU, Rogers TM, Solomon B, Pao W, Carter SL, Getz G, Hayes D, Wilkerson MD, Thunnissen E, Travis WD, Perner S, Wright G, Brambilla E, Büttner R, Wolf J, Thomas RK, Gabler F, Wilkening I, Müller C, Dahmen I, Menon R, König K, Albus K, Merkelbach-Bruse S, Fassunke J, Schmitz K,Kuenstlinger H, Kleine MA, Binot E, Querings S, Altmüller J, Bäßmann I, Nürnberg P, Schneider PM, Bogus M, Büttner R, Perner S, Russell P,Thunnissen E, Travis WD, Brambilla E, Soltermann A, Moch H, Brustugun OT, Solberg S, Lund-Iversen M, Helland Å, Muley T, Hoffmann H, Schnabel PA, Chen Y, Groen H, Timens W, Sietsma H, Clement JH, Weder W, Sänger J, Stoelben E, Ludwig C, Engel-Riedel W, Smit E, Heideman DA, Snijders PJ, Nogova L, Sos ML, Mattonet C, Töpelt K, Scheffler M, Goekkurt E, Kappes R, Krüger S, Kambartel K, Behringer D, Schulte W, Galetke W,Randerath W, Heldwein M, Schlesinger A, Serke M, Hekmat K, Frank KF, Schnell R, Reiser M, Hünerlitürkoglu AN, Schmitz S, Meffert L, Ko YD, Litt-Lampe M, Gerigk U, Fricke R, Besse B, Brambilla C, Lantuejoul S, Lorimier P, Moro-Sibilot D, Cappuzzo F, Ligorio C, Damiani S, Field JK, Hyde R, Validire P, Girard P, Muscarella LA, Fazio VM, Hallek M, Soria JC, Carter SL, Getz G, Hayes D, Wilkerson MD, Achter V, Lang U, Seidel D, Zander T,Heukamp LC, Peifer M, Bos M, Pao W, Travis WD, Brambilla E, Büttner R, Wolf J, Thomas RK, Büttner R, Wolf J, Thomas RK. A genomic-based classification of human lung tumors. Clinical Lung Cancer Genome Project (CLCGP); Network Genomic Medicine (NGM). Sci Transl Med. 2013 30;5(209):209ra153
• Naumann-Winter F, Greb A, Borchmann P, Bohlius J, Engert A, Schnell R. First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies. Cochrane Database Syst Rev. 2012; Oct 17;10:CD004626
• Schildhaus HU, Heukamp LC, Merkelbach-Bruse S, Riesner K, Schmitz K, Binot E, Paggen E, Albus K, Schulte W, Ko YD, Schlesinger A, Ansén S, Engel-Riedel W, Brockmann M, Serke M, Gerigk U, Huss S, Göke F, Perner S, Hekmat K, Frank KF, Reiser M, Schnell R, Bos M, Mattonet C, Sos M, Stoelben E, Wolf J, Zander T, Buettner R. Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Mod Pathol. 2012 Nov;25(11):1473-80
• Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky TC, Weihrauch MR, Cremer B, Kashkar H, Odenthal M, Augustin HG, Schmiegel W, Hallek M, Hacker UT. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer. 2010 Oct 26;103(9):1407-14.
• Dietlein M, Börner SM, Fischer T, Hansen H, Schnell R, Zimmermanns B, Tawadros S, Engert A, Staak O, Pogge von Strandmann E, Kobe C, Schicha H, Schomäcker K. Development of anti-CD30 radioimmunoconstructs (RICs) for treatment of Hodgkin's lymphoma. Studies with cell lines and animal studies. Nuklearmedizin. 2010;49(3):97-105.
• Schnell R, Dietlein M, Schomäcker K, Kobe C, Borchmann P, Schicha H, Hallek M, Engert A. Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma. Onkologie 2008; 31(1-2): 49-51.
• Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Rudiger T, Borchmann P, Schnell R, Diehl V, Engert A, Reiser M. Rituximab in relapsed lymphocyte-predominant Hodgkin Lymphoma: Long-term results of a phase-II trial of the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008; 111(1):109-11. Epub 2007 Oct 15.
• Schnell R, Borchmann P. SGN-30 (Seattle genetics). Curr Opin Mol Ther. 2006; 8(2): 164-72.
• Pogge von Strandmann E, Hansen HP, Reiners KS, Schnell R, Borchmann P, Merkert S, Simhadri VR, Draube A, Reiser M, Purr I, Hallek M, Engert A. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 2006; 107(5): 1955-62.
• Borchmann P, Behringer K, Josting A, Rueffer JU, Schnell R, Diehl V, Engert A, Kvasnicka HM, Thiele J. Secondary malignancies after successful primary treatment of malignant Hodgkin's lymphoma. Pathologe. 2006; 27(1): 47-52.
• Schomacker K, Dietlein M, Schnell R, Pinkert J, Eschner W, Zimmermanns B, Fischer T, Engert A, Schicha H. Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan. Clinical considerations, radiopharmacy, radiation protection, perspectives. Nuklearmedizin. 2005; 44(4): 166-77.
• Elter T, Borchmann P, Schulz H, Reiser M, Trelle S, Schnell R , Jensen M, Staib P, Schinkothe T, Stutzer H, Rech J, Gramatzki M, Aulitzky W, Hasan I, Josting A, Hallek M, Engert A. Fludarabine in Combination With Alemtuzumab Is Effective and Feasible in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: Results of a Phase II Trial. J Clin Oncol. 2005; 23 (28): 7024-31.
• Schnell R, Dietlein M, Staak JO, Borchmann P, Schomaecker K, Fischer T, Eschner W, Hansen H, Morschhauser F, Schicha H, Diehl V, Raubitschek A, Engert A. Treatment of refractory Hodgkin lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody (131I-Ki-4). J Clin Oncol. 2005; 23(21): 4669-78.
• Dietlein M, Pels H, Schulz H, Staak O, Borchmann P, Schomacker K, Fischer T, Eschner W, Strandmann EP, Schicha H, Engert A, Schnell R. Imaging of central nervous system lymphomas with iodine-123 labeled rituximab. Eur J Haematol. 2005; 74(4):348-52.
• Matthey B, Borchmann P, Schnell R, Tawadros S, Lange H, Huhn M, Klimka A, Tur MK, Barth S, Engert A, Hansen HP. Metalloproteinase inhibition augments antitumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA' against human lymphomas in vivo. Int J Cancer. 2004; 111(4): 568-74.
• Castelletti D, Fracasso G, Righetti S, Tridente G, Schnell R, Engert A, Colombatti M A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin. Clin Exp Immunol. 2004; 136(2): 365-72.
• Borchmann P, Morschhauser F, Parry A, Schnell R, Harousseau JL, Gisselbrecht C, Rudolph C, Wilhelm M, Gunther H, Pfreundschuh DM, Camboni G, Engert A. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas. Haematologica. 2003; 88(8): 888-94.
• Borchmann P, Treml JF, Hansen H, Gottstein C, Schnell R, Staak O, Zhang HF, Davis T, Keler T, Diehl V, Graziano RF, Engert A. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood. 2003; 102(10): 3737-42
• Schnell R, Borchmann P, Staak JO, Schindler J, Ghetie V, Vitetta ES, Engert A. Clinical evaluation of Ricin A-chain immunotoxins in patients with Hodgkin´s lymphoma. Ann. Oncol. 2003; 14(5): 729-36.
• Staak JO, Dietlein M, Engert A, Weihrauch MR, Schomacker K, Fischer T, Eschner W, Borchmann P, Diehl V, Schicha H, Schnell R. Hodgkin's lymphoma in nuclear medicine: diagnostic and therapeutic aspects. Nuklearmedizin. 2003; 42(1): 19-24.
• Borchmann P, Schnell R, Fuss I, Manzke O, Davis T, Lewis LD, Behnke D, Wickenhauser C, Schiller P, Diehl V, Engert A. Phase I trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood. 2002; 100(9): 3101-7.
• Schnell R, Staak O, Borchmann P, Schwartz C, Matthey B, Hansen H, Schindler J, Ghetie V, Vitetta ES, Diehl V, Engert A. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin. Cancer Res. 2002; 8(6): 1779-86.
• Borchmann P, Schnell R, Knippertz R, Staak JO, Camboni GM, Bernareggi A, Hubel K, Staib P, Schulz A, Diehl V, Engert A. Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. Ann. Oncol. 2001; 12(5): 661-7.
• Barth S, Huhn M, Matthey B, Tawadros S, Schnell R, Schinköthe T, Diehl V, Engert A. Ki-4(scFv)-ETA´, a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood 2000; 95: 3909-3914.
• Schnell R, Vitetta E, Schindler J, Borchmann P, Barth S, Ghetie V, Hell K, Drillich S, Diehl V, Engert A. Treatment of refractory Hodgkin´s lymphoma patients with an anti-CD25 ricin A-chain immunotoxin. Leukemia 2000, 14: 129-135.
• Barth S, Huhn M, Matthey B, Schnell R, Tawadros S, Schinköthe T, Lorenzen J, Diehl V, Engert A. Recombinant anti-CD25 immunotoxin RFT5(scFv)-ETA´demonstrates successful elimination of disseminated human Hodgkin Lymphoma in SCID mice. Int. J. Cancer 2000; 86: 718-724.
• Hubel K, Hegener K, Schnell R, Mansmann G, Oberhauser F, Staib P, Diehl V, Engert A. Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia. Ann. Hematol. 1999; 78(2): 73-7.
• Schnell R, Vitetta E, Schindler J, Barth S, Winkler U, Borchmann P, Hansmann ML, Diehl V, Ghetie V, Engert A. Experimental and clinical trials with an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma. Leuk. Lymphoma 1998; 30(5-6):525-37.
• Reiser M, Schnell R, Straub G, Borchmann P, Wilhelm M, Ubelacker R, Wormann B, Munch R, Diehl V, Engert A. DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma. Leuk Lymphoma 1998; 31(3-4): 359-66.
• Hubel K, Tesch H, Kroger B, Schnell R, Borchmann P, Diehl V, Engert A. A phase I/II study of idarubicin, dexamethasone and interferon-alpha (I-Dexa) in patients with relapsed or refractory multiple myeloma. Leukemia 1997; 11 Suppl 5: S47-51 .
• Winkler U, Barth S, Schnell R, Diehl V, Engert A. The emerging role of immunotoxins in leukemia and lymphoma. Ann. Oncol. 1997; 8: 139-146.
• Engert A, Schnell R, Küpper F, Reiser M, Engelhard M, Wilhelm M, Lathan B, Baltes-Engler S, Winterhalter B, Scheulen ME, Dederichs B, Tesch H, Wormann B, Diehl V. A phase-II study with Idarubicin, Ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed high-grade non-Hodgkin´s lymphoma. Leuk. Lymphoma 1997; 24: 513-522.
• Engert A, Diehl V, Schnell R, Radszuhn A, Hatwig MT, Drillich S, Schon G, Bohlen H, Tesch H, Hansmann ML, Barth S, Schindler J, Ghetie V, Uhr J, Vitetta E. A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin´s lymphoma. Blood 1997; 89: 403-410.
• Schnell R, Katouzi AA, Linnartz C, Schoen G, Drillich S, Hansmann ML, Schiefer D, Barth S, Zangemeister-Wittke U, Stahel RA, Diehl V, Engert A. Potent antitumor effects of an anti-CD24 ricin A-chain immunotoxin in vitro and in a disseminated human Burkitt´s lymphoma model in SCID mice. Int. J. Cancer 1996, 66: 526-531.
• Ghetie V, Engert A, Schnell R, Vitetta ES. The in vivo anti-tumor activity of immunotoxins containig two versus one deglycosylated ricin A-chains. Cancer letters 1995; 98: 97-101.
• Engert A, Gottstein C, Bohlen H, Winkler U, Schön G, Manske O, Schnell R, Diehl V, Thorpe P: Cocktails of ricin A-chain immunotoxins against different antigens on Hodgkin and Sternberg-Reed cells have superior antitumor effects against H-RS cells in vitro and solid Hodgkin tumors in mice. Int. J. Cancer 1995; 63: 2304-309.
• Schnell R, Linnartz C, Katouzi A, Schon G, Bohlen H, Horn-Lohrens O, Parwaresch RM, Lange H, Diehl V, Lemke H, Engert A. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen. Int. J. Cancer 1995; 63: 238-244.

2. Buchbeiträge

• Schnell R, Engert A. Monoklonale Antikörper in der Therapie von niedrig-malignen Lymphomen. In M. Dreyling: Indolente Non-Hodgkin-Lymphome. Uni-Med Verlag AG, Bremen, London, Boston 2009, 55-71.
• Staak JO, Schnell R, Borchmann P, Engert A. Novel Treatment Techniques for Hodgkin Lymphoma. In RT Hoppe, PT Mauch, JO Armitage, V Diehl LM Weiss: Hodgkin Lymphoma. Lippincott Williams & Wilkins, Philadelphia 2007, 205-222.
• Schnell R, Dietlein M, Engert A. Radioimmuntherapie von Hodgkin-Lymphomen: Rationale und klinische Ergebnisse.. In L. Trümper: Radioimmuntherapie in der Hämatologie und Onkologie. Uni-Med Verlag AG, Bremen, London, Boston 2007, 68-74.
• Schnell R, Engert A. Ricin-based immunotoxins/cytotoxins. Ricin immunotoxins in lymphomas: Clinical application. In Kawakami, Aggarwal, Puri: Cytotoxins and immunotoxins for cancer therapy. CRC Press, Boca Raton, London, New York, Washington, D.C. 2005, 71-93.
• Borchmann P, Schnell R, Engert A. Hodgkin Lymphoma: Experimental strategies. In Diehl, Josting: 25 years German Hodgkin Study Group. Urban und Vogel, München 2004, 100-112.
• Schnell R, Barth S, Engert A. Der therapeutische Einsatz von monoklonalen Antikörpern und Immuntoxinen beim Morbus Hodgkin. In Kneba, Dreger, Pantel: Antikörpertherapie der Hämatologie und Onkologie. Uni-Med Verlag AG, Bremen, London, Boston 2001, 94-105.
• Schnell R, Barth S, Diehl V, Engert A. Future treatment strategies: fact or fiction? In V. Diehl: Hodgkin´s disease. Bailliere´s Clinical Hematology 1996, 573-594.

3. Übersichtsartikel

• Klimm B, Schnell R, Diehl V, Engert A. Current treatment and immunotherapy of Hodgkin's lymphoma. Haematologica. 2005; 90(12): 1680-92.
• Borchmann P, Schnell R. The role of pixantrone in the treatment of non-Hodgkin's lymphoma. Expert Opin Investig Drugs. 2005; 14 (8): 1055-61.
• Borchmann P, Schnell R, Engert A. Immunotherapy of Hodgkin's lymphoma. Eur J Haematol. 2005; 75 Suppl 66:159-65.
• Borchmann P, Schnell R, Schulz H, Engert A. Monoclonal antibody based immunotherapy of Hodgkin´s lymphoma. Curr Opinion Inv drugs 2004; 5(12):1262-7.
• Schnell R, Borchmann P, Schulz H, Engert A. Current strategies of antibody-based treatment in Hodgkin's disease. Ann. Oncol. 2002; 13 Suppl 1 :57-66.
• Schnell R, Hiddemann W, Diehl V, Engert A. Klinischer Einsatz monoklonaler Antikörper bei Lymphomen. Internist 2001; 42(6): 815-6, 819-826.
• Buske C, Engert A, Schnell R, Diehl V, Hiddemann W. Monoklonale Antikörper in der Therapie maligner Lymphome. Internist 1998; 39(12):1205-1214.
• Borchmann P, Schnell R, Diehl V, Engert A: New drugs in the treatment of Hodgkin's disease. Ann. Oncol. 1998; 9 Suppl 5: S103-108
• Schnell R, Barth S, Diehl V, Engert A. Non-Hodgkin´s lymphoma. A review of immunotherapeutic approaches to treatment. Biodrugs 1997; 8 (3): 216-234.
• Engert A, Schnell R, Barth S, Diehl V. Immuntherapeutische Strategien bei Lymphomen. Internist 1997; 38: 150-156.
• Schnell R, Barth S, Diehl V, Engert A. Non-Hodgkin's Lymphoma: A Review of Immunotherapeutic Approaches to Treatment. BioDrugs. 1997; 8(3): 216-34.
• Borchmann P, Hübel K, Schnell R, Engert A. Idarubicin: a brief overview on pharmacology and clinical use. Int. J. Clin. Pharmacol. Ther. 1997; 35(2): 80-83.
• Barth S, Schnell R, Diehl V, Engert A. Development of immunotoxins for potential clinical use in Hodgkin´s disease. Ann Oncol 1996; 7: 135-141.
• Engert A, Schnell R, Lathan B, Diehl V. Grenzen und Stellenwert der Chemotherapie bei älteren Patienten. Med. Klin. 1994; 15; 89 (11): 603-610.